ArticleCancer research2018
An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors.
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.Proceedings of the National Academy of Sciences of the United States of America · 2019Trial
- Evaluation of Inflammatory Biomarkers Gal-1 and IL-1β and Liver Enzyme Activities in Gastric Cancer Patients Pre- and Post-Chemotherapy: A Case-Control Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Profiling type I and II interferon responses reveals distinct subgroups of pediatric patients with autoinflammatory disorders.The journal of allergy and clinical immunology. Global · 2025Article
- Inflammation Factors and Genistein Supplementation in Cancer-Preliminary Research.Current issues in molecular biology · 2024Article
- NLRP3 and cancer: Pathogenesis and therapeutic opportunities.Pharmacology & therapeutics · 2023Review
- Crohn's disease and breast cancer: a literature review of the mechanisms and treatment.Internal and emergency medicine · 2023Review
- Subcapsular Sinus Macrophages Promote Melanoma Metastasis to the Sentinel Lymph Nodes via an IL1α-STAT3 Axis.Cancer immunology research · 2022Article
- Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring.Frontiers in immunology · 2022Article
- IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.NPJ breast cancer · 2021Article
- A MyD88/IL1R Axis Regulates PD-1 Expression on Tumor-Associated Macrophages and Sustains Their Immunosuppressive Function in Melanoma.Cancer research · 2021Article
- Key Factor Regulating Inflammatory Microenvironment, Metastasis, and Resistance in Breast Cancer: Interleukin-1 Signaling.Mediators of inflammation · 2021Review
- Identification of key pathways and genes shared between Crohn's disease and breast cancer using bioinformatics analysis.Oncology letters · 2020Article
- Oxymatrine suppresses IL-1β-induced degradation of the nucleus pulposus cell and extracellular matrix through the TLR4/NF-κB signaling pathway.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival: synergistic induction of IL-6 secretion by OSM and IL-1β.Oncotarget · 2019Article
- IL-1 Family Members in Cancer; Two Sides to Every Story.Frontiers in immunology · 2019Review
- The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice.Oncology and therapy · 2018Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 2 countries.
Funding
Abstract
In this issue of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.